Bioxcel Therapeutics Stock Investor Sentiment

BTAI Stock  USD 2.28  0.15  7.04%   
Under 68 percent of all BioXcel Therapeutics' traders are curious in acquiring. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that a large number of traders are confidant. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.

Comfort Level 68

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use BioXcel Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward BioXcel Therapeutics.

BioXcel Historical Sentiment

Although BioXcel Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding BioXcel, such as negative comments on social media and news outlets, may cause fear in the market and push BioXcel Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of BioXcel.
  

BioXcel Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at www.macroaxis.com         
Disposition of 217 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Macroaxis News
3 days ago at www.macroaxis.com         
Disposition of 162 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Tr...
Yahoo News
few days ago at gurufocus.com         
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 ...
Gurufocus Stories at Macroaxis
six days ago at zacks.com         
Acquisition by Mack David J. of 325077 shares of BioXcel Therapeutics subject to Rule 16b-3
zacks News
over a week ago at finance.yahoo.com         
Why BioXcel Therapeutics, Inc. Soared Last Week
Yahoo News
over a week ago at gurufocus.com         
BioXcel Therapeutics Announces 33 percent Enrollment in SERENITY At-Hom
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Disposition of 2610 shares by Vimal Mehta of BioXcel Therapeutics subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over a week ago at globenewswire.com         
BioXcel Therapeutics Announces 33 percent Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Tria...
Macroaxis News: globenewswire.com
over a week ago at finance.yahoo.com         
BioXcel Therapeutics Announces 33 percent Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Tria...
Yahoo News
over a week ago at zacks.com         
Disposition of 521 shares by Steinhart Richard I of BioXcel Therapeutics subject to Rule 16b-3
zacks News
over a week ago at zacks.com         
ScPharmaceuticals, Inc. Expected to Beat Earnings Estimates Should You Buy?
zacks News
over a week ago at zacks.com         
Fate Therapeutics Reports Q4 Loss, Tops Revenue Estimates
zacks News
over a week ago at finance.yahoo.com         
BioXcel Therapeutics Announces Closing of 14 Million Registered Direct Offering
Yahoo News
over a week ago at gurufocus.com         
BioXcel Therapeutics Announces Closing of 14 Million Registered Direct Offering
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about BioXcel Therapeutics that are available to investors today. That information is available publicly through BioXcel media outlets and privately through word of mouth or via BioXcel internal channels. However, regardless of the origin, that massive amount of BioXcel data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of BioXcel Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioXcel Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioXcel Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioXcel Therapeutics alpha.

BioXcel Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 225 shares by Frank Yocca of BioXcel Therapeutics at 0.3512 subject to Rule 16b-3
12/16/2024
2
Acquisition by Mack David J. of 27089 shares of BioXcel Therapeutics subject to Rule 16b-3
12/31/2024
3
Insider Trading
01/15/2025
4
BioXcel Therapeutics announces 1-for-16 reverse stock split - MSN
02/18/2025
5
Acquisition by Mack David J. of 1693 shares of BioXcel Therapeutics subject to Rule 16b-3
02/28/2025
6
BioXcel Therapeutics Announces 14 Million Registered Direct Offering
03/03/2025
7
Disposition of 1693 shares by Mack David J. of BioXcel Therapeutics subject to Rule 16b-3
03/04/2025
8
Disposition of 521 shares by Steinhart Richard I of BioXcel Therapeutics subject to Rule 16b-3
03/06/2025
9
BioXcel Therapeutics Announces 33 percent Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trialfor Acute Treatment of Agitation Associated with Bipolar Di...
03/07/2025
10
Acquisition by Mack David J. of 325077 shares of BioXcel Therapeutics subject to Rule 16b-3
03/10/2025
11
Acquisition by Oneill Vincent of 21250 shares of BioXcel Therapeutics subject to Rule 16b-3
03/14/2025

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated